Fibrobiologics Inc (FBLG) Stock Price, Quote & News

Company Profile

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It al...

Industry: Biotechnology

Sector: Healthcare

Phone: 281 671 5150

Website: fibrobiologics.com

Address:

455 East Medical Center Boulevard, Suite 300, Houston, United States

DarkPooling May. 29 at 6:30 PM

$MODD $AKTX $AGL $SVRN $FBLG chart

0 · Reply

Niddi May. 28 at 4:59 PM

$FBLG I think something special is brewing. Looking at the price movement and volume.

0 · Reply

MisoHawny May. 28 at 4:23 PM

$FBLG we will likely revisit 1.01 by July

0 · Reply

Niddi May. 27 at 2:38 AM

$FBLG

0 · Reply

Niddi May. 22 at 1:31 PM

$FBLG This company is the future of medicine

0 · Reply

DARKP00L May. 22 at 12:50 PM

$FBLG 08:35 on May. 22 2026 FibroBiologics Announces Preclinical Data From Its CYPS317 Program For Psoriasis Was Presented At The Society For Investigative Dermatology Meeting, May 13-15 #tradeideas

0 · Reply

ReturnOfEsquire May. 21 at 2:22 AM

$FBLG How could anyone be bullish here? Look at the all-time chart.

0 · Reply

KardiTheViking May. 20 at 2:17 PM

$FBLG this turd is setting a positive divergence, but any real potential impossible uptrend would be only above the rose line at 6.58. Honestly I do not see it possible in the near term. We have to wait months for the results from the 1/2 trial to have remotedly the opportunity of a squeeze

1 · Reply

Niddi May. 19 at 7:16 PM

$FBLG Time to add.

0 · Reply

Niddi May. 18 at 1:06 PM

$FBLG Applied for new patent.

0 · Reply

FibroBiologics presents preclinical data from CYPS317 program

May 22, 2026, 8:30 AM EDT - 7 days ago

FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting

May 18, 2026, 8:30 AM EDT - 11 days ago

FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics

2026-05-11T14:42:59.000Z - 18 days ago

FibroBiologics expands fibroblast-based platform to target Hantavirus

May 11, 2026, 8:30 AM EDT - 18 days ago

FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus

May 5, 2026, 8:30 AM EDT - 24 days ago

FibroBiologics CEO Issues Letter to Shareholders

May 5, 2026, 8:00 AM EDT - 24 days ago

FibroBiologics Proxy statement: Proxy filing

May 5, 2026, 8:00 AM EDT - 24 days ago

FibroBiologics Proxy statement: Proxy filing

2026-05-04T21:05:51.000Z - 25 days ago

FibroBiologics says fibroblast spheroids drive burn healing, reduce scarring

May 4, 2026, 4:01 PM EDT - 25 days ago

FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring

2026-05-04T13:30:12.000Z - 25 days ago

FibroBiologics releases first batch of CYWC628 for Phase 1/2 trial

May 4, 2026, 8:30 AM EDT - 25 days ago

FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

2026-05-04T12:28:08.000Z - 25 days ago

FibroBiologics downgraded to Hold from Buy at Maxim

2026-04-30T22:00:27.000Z - 4 weeks ago

FibroBiologics reports Q1 net loss roughly ($5M)

Apr 30, 2026, 5:55 PM EDT - 4 weeks ago

FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update

Apr 30, 2026, 8:30 AM EDT - 4 weeks ago

FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026

Apr 30, 2026, 7:00 AM EDT - 4 weeks ago

FibroBiologics Quarterly report: Q1 2026

Apr 30, 2026, 7:00 AM EDT - 4 weeks ago

FibroBiologics Earnings release: Q1 2026

Apr 22, 2026, 8:00 AM EDT - 5 weeks ago

FibroBiologics Proxy statement: Proxy filing

2026-04-20T20:23:12.000Z - 5 weeks ago

FibroBiologics announces compliance with all Nasdaq listing requirements

Apr 20, 2026, 4:01 PM EDT - 5 weeks ago

FibroBiologics Compliant with All Nasdaq Listing Requirements

2026-04-16T14:53:32.000Z - 6 weeks ago

FibroBiologics target adjusted to $8 at H.C. Wainwright after reverse split

Apr 10, 2026, 8:30 AM EDT - 7 weeks ago

FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity

Apr 2, 2026, 4:01 PM EDT - 2 months ago

FibroBiologics Announces Closing of $3 Million Public Offering

2026-04-01T00:05:13.000Z - 2 months ago

FibroBiologics prices $3M public offering

Mar 31, 2026, 8:00 PM EDT - 2 months ago

FibroBiologics Announces Pricing of $3 Million Public Offering

2026-03-31T20:41:40.000Z - 2 months ago

FibroBiologics manufactures first batch of CYWC628 drug product for trials

Mar 31, 2026, 4:15 PM EDT - 2 months ago

FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial

2026-03-27T23:50:16.000Z - 2 months ago

Fibrobiologics Inc trading halted, news pending

2026-03-27T21:25:14.000Z - 2 months ago

FibroBiologics files to sell 1.14M shares of common stock, warrants

Mar 27, 2026, 8:00 AM EDT - 2 months ago

FibroBiologics Registration statement: Registration filing

2026-03-26T11:21:11.000Z - 2 months ago

FibroBiologics downgraded to Hold from Buy at D. Boral Capital

2026-03-25T20:50:15.000Z - 2 months ago

FibroBiologics announces 1-for-20 reverse stock split

Mar 25, 2026, 4:30 PM EDT - 2 months ago

FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement

2026-03-12T12:48:33.000Z - 2 months ago

FibroBiologics announces expansion of wound care platform

Mar 12, 2026, 8:30 AM EDT - 2 months ago

FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

2026-03-05T13:48:24.000Z - 3 months ago

FibroBiologics completes site onboarding for Phase 1/2 trial of CYWC628

$FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers$

Mar 5, 2026, 8:30 AM EST - 3 months ago

FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

2026-03-02T13:48:25.000Z - 3 months ago

FibroBiologics announces issuance of U.S. patent covering fibroblast therapy

Mar 2, 2026, 8:30 AM EST - 3 months ago

FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

Feb 26, 2026, 8:30 AM EST - 3 months ago

FibroBiologics to Present at the BIO Investment & Growth Summit

2026-02-26T11:11:16.000Z - 3 months ago

FibroBiologics price target lowered to $4 from $5 at H.C. Wainwright

Feb 24, 2026, 4:30 PM EST - 3 months ago

FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update

Feb 24, 2026, 7:00 AM EST - 3 months ago

FibroBiologics Earnings release: Q4 2025

Feb 24, 2026, 7:00 AM EST - 3 months ago

FibroBiologics Annual report: Q4 2025

Feb 24, 2026, 7:00 AM EST - 3 months ago

FibroBiologics Annual report: Q4 2025

2026-02-23T13:40:30.000Z - 3 months ago

FibroBiologics granted extension by Nasdaq to regain compliance

Feb 23, 2026, 8:30 AM EST - 3 months ago

FibroBiologics Granted Extension by Nasdaq to Regain Compliance

Feb 20, 2026, 12:00 PM EST - 3 months ago

FibroBiologics Transcript: EGM 2026

Feb 10, 2026, 8:30 AM EST - 3 months ago

FibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown University

Feb 5, 2026, 8:30 AM EST - 4 months ago

FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

Jan 20, 2026, 8:30 AM EST - 4 months ago

FibroBiologics to Present at the DealFlow Discovery Conference

Jan 6, 2026, 8:30 AM EST - 5 months ago

FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference

Jan 5, 2026, 8:30 AM EST - 5 months ago

FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease

Dec 31, 2025, 8:30 AM EST - 5 months ago

FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

Dec 29, 2025, 7:00 AM EST - 5 months ago

FibroBiologics Proxy statement: Proxy Filing

Dec 29, 2025, 7:00 AM EST - 5 months ago

FibroBiologics Proxy statement: Proxy Filing

Dec 23, 2025, 7:00 AM EST - 5 months ago

FibroBiologics Registration statement: Registration Filing

Dec 18, 2025, 7:00 AM EST - 5 months ago

FibroBiologics Proxy statement: Proxy Filing

Dec 18, 2025, 7:00 AM EST - 5 months ago

FibroBiologics Proxy statement: Proxy Filing

Dec 16, 2025, 4:05 PM EST - 5 months ago

FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 15, 2025, 8:00 AM EST - 5 months ago

FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 10, 2025, 8:30 AM EST - 6 months ago

FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions

Nov 26, 2025, 8:30 AM EST - 6 months ago

FibroBiologics Announces Payoff of Outstanding Debt

Nov 25, 2025, 4:05 PM EST - 6 months ago

FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 24, 2025, 9:00 AM EST - 6 months ago

FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

$FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers$

Nov 20, 2025, 8:00 AM EST - 6 months ago

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

Nov 19, 2025, 7:03 PM EST - 6 months ago

FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 19, 2025, 8:36 AM EST - 6 months ago

FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 31, 2025, 4:30 PM EDT - 7 months ago

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 31, 2025, 4:00 PM EDT - 7 months ago

FibroBiologics Earnings release: Q3 2025

Oct 31, 2025, 4:00 PM EDT - 7 months ago

FibroBiologics Quarterly report: Q3 2025

Oct 24, 2025, 8:30 AM EDT - 7 months ago

FibroBiologics to Present at Bio-Europe 2025

Oct 14, 2025, 8:30 AM EDT - 8 months ago

FibroBiologics to Present at the 2025 ThinkEquity Conference

Sep 23, 2025, 8:30 AM EDT - 8 months ago

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

Sep 12, 2025, 8:30 AM EDT - 9 months ago

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

Sep 11, 2025, 8:30 AM EDT - 9 months ago

FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

Sep 10, 2025, 8:30 AM EDT - 9 months ago

FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies

Aug 27, 2025, 8:30 AM EDT - 9 months ago

FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Jul 31, 2025, 4:30 PM EDT - 10 months ago

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 31, 2025, 4:00 PM EDT - 10 months ago

FibroBiologics Earnings release: Q2 2025

Jul 31, 2025, 4:00 PM EDT - 10 months ago

FibroBiologics Quarterly report: Q2 2025

Jul 28, 2025, 8:30 AM EDT - 10 months ago

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

Jul 11, 2025, 8:30 AM EDT - 11 months ago

FibroBiologics to Present at the Advanced Wound Care Summit USA

Jul 9, 2025, 8:30 AM EDT - 11 months ago

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank

Jul 7, 2025, 4:35 PM EDT - 11 months ago

FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10

Jun 16, 2025, 4:35 PM EDT - 1 year ago

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

Jun 16, 2025, 9:50 AM EDT - 1 year ago

FibroBiologics to Present at the BIO International Convention 2025

DarkPooling May. 29 at 6:30 PM

$MODD $AKTX $AGL $SVRN $FBLG chart

0 · Reply

Niddi May. 28 at 4:59 PM

$FBLG I think something special is brewing. Looking at the price movement and volume.

0 · Reply

MisoHawny May. 28 at 4:23 PM

$FBLG we will likely revisit 1.01 by July

0 · Reply

Niddi May. 27 at 2:38 AM

$FBLG

0 · Reply

Niddi May. 22 at 1:31 PM

$FBLG This company is the future of medicine

0 · Reply

DARKP00L May. 22 at 12:50 PM

$FBLG 08:35 on May. 22 2026 FibroBiologics Announces Preclinical Data From Its CYPS317 Program For Psoriasis Was Presented At The Society For Investigative Dermatology Meeting, May 13-15 #tradeideas

0 · Reply

ReturnOfEsquire May. 21 at 2:22 AM

$FBLG How could anyone be bullish here? Look at the all-time chart.

0 · Reply

KardiTheViking May. 20 at 2:17 PM

1 · Reply

Niddi May. 19 at 7:16 PM

$FBLG Time to add.

0 · Reply

Niddi May. 18 at 1:06 PM

$FBLG Applied for new patent.

0 · Reply

Niddi May. 18 at 1:05 PM

$FBLG Here we go. Just a tiny sample of what’s to come.

0 · Reply

SuperGreenToday May. 18 at 12:39 PM

$FBLG

0 · Reply

mterrell May. 16 at 4:48 PM

$FBLG can anyone sell me on this stock and when we might hear good news

0 · Reply

Niddi May. 15 at 2:05 PM

$FBLG Today is the presentation at Society of Investigative Dermatology.

0 · Reply

Niddi May. 14 at 7:43 PM

$FBLG Another good opportunity to add.

0 · Reply

Darksoul May. 13 at 7:53 PM

$FBLG strong volume in buys into the close. This could get interesting if we break $1.20-$1.30 range. Ideally id love to get over $2.00 and it had potential to go parabolic.

0 · Reply

Niddi May. 13 at 3:58 PM

$FBLG This is exactly how it works for new companies. One has to wait and invest wisely. The pipeline is awesome.

0 · Reply

Darksoul May. 13 at 3:43 PM

$FBLG true. But if trials go good it will no longer be an issue. But yea its risky

0 · Reply

Darksoul May. 13 at 3:42 PM

$FBLG

0 · Reply

WiseGuyInvestin May. 13 at 1:25 AM

$FBLG the biggest problem with the company has been and always will be MONEY. They don’t even have one quarter worth of cash! How are they going to survive without diluting to oblivion!

1 · Reply

Darksoul May. 12 at 8:21 PM

$FBLG conference tomorrow. For anyone out there with rib or disk issues.. u gotta at least root for these guys to be successful.

1 · Reply

Niddi May. 12 at 7:28 PM

$FBLG This company has so much potential, given the number of clinically useful products for medical conditions that has no satisfactory treatments, I won’t be surprised if it touches $10 by the end of this year. Just my opinion.

1 · Reply

Market Cap	5.83M
Revenue (ttm)	0.00
Net Income (ttm)	-18.65M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	64,800
Avg Vol	536,575
Day's Range	N/A - N/A
Shares Out	5.21M
Stochastic %K	87%
Beta	1.16
Analysts	Sell
Price Target	$8.00